Drug intelligence / Profile preview

VADA

Development stage: Preclinical
Lead developer: Day One Biopharmaceuticals
Modality: Small Molecules

Overview

Sprint Bioscience is developing a small molecule inhibitor of Vaccinia-Related Kinase 1 (VRK1) for the treatment of solid tumors, specifically targeting glioblastoma and neuroblastoma. The program, designated VADA, leverages the concept of synthetic lethality; VRK1 inhibition is selectively toxic to cancer cells that have low expression of the related kinase VRK2, a genetic profile found in the majority of high-grade gliomas and high-risk neuroblastomas. VRK1 is a key regulator of the DNA damage response and cell cycle progression. The program was briefly licensed to Day One Biopharmaceuticals before being returned to Sprint Bioscience in 2025. It is currently in the preclinical stage of development.

Other names: VRK1 inhibitorVRK-1 inhibitorVRK 1 inhibitor

Targets

VRK1 (Vaccinia-related kinase 1)

Beyond the preview

Go deeper on VADA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VADA.

Explore the full profile